A Centre for Clinical Service and Research & Development
The Shimadzu-CGH Clinomics Centre (SC3) was officially opened by Deputy Prime Minister of Singapore and Coordinating Minister for Economic Policies, Mr Heng Swee Keat on 27 January 2021. The coming together of the clinical and research expertise of CGH and SingHealth with Shimadzu’s diagnostic and analytical capabilities at SC3 will contribute to medical care and treatment in Singapore.
Deputy Prime Minister Heng views the mass spectrometer, which detects and measures multiple test compounds in a single sample with greater accuracy, at the Centre.
At SC3, clinical applications are developed using mass spectrometry technologies and instruments to enhance the standard of care for patients.
SC3 aims to excel in both clinical service as well as research and development. The centre continually develops cliical, analytical and operational capabilities in mass spectrometry with novel clinical tests of improved diagnostic accuracy and shorter turnaround time. The centre also serves as a research incubator to develop translatable clinical tests and expand the CGH clinical research portfolio using mass spectrometry technologies.
Core Technology – Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS)
The core technology being used at SC3 is state-of-the-art mass spectrometry. This advanced technology comprises a front-end ultra-high performance liquid chromatography (UHPLC) coupled to a triple quadruple mass spectrometer for the separation and accurate quantification of test compounds in clinical samples. With multiplexing capability and ultra-high sensitivity, only a very little amount of clinical sample is required for the measurement of multiple test compounds. Leveraging the technology of mass spectrometry powered by analytical intelligence, SC3 is able to improve clinical diagnostic accuracies for patients.
Click on the links below to learn more.
Subscribe to our mailing list to get the updates to your email inbox...
